NASDAQ: RNTXRein Therapeutics Inc Stock
$1.70+0.05 (+3.03%)
Updated Apr 17, 2025
RNTX Price
$1.70
Fair Value Price
N/A
Market Cap
$37.39M
52 Week Low
$1.35
52 Week High
$5.43
P/E
-0.48x
P/B
0.69x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$62.88M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.14
Operating Cash Flow
-$22M
Beta
1.03
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
RNTX Overview
Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine RNTX's potential to beat the market
- RNTX doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
RNTX
RankedUnranked of 463
RankedUnranked of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important RNTX news, forecast changes, insider trades & much more!
RNTX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RNTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RNTX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
RNTX is good value based on its book value relative to its share price (0.69x), compared to the US Biotechnology industry average (4.05x)
P/B vs Industry Valuation
RNTX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more RNTX due diligence checks available for Premium users.
Valuation
RNTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.48x
Industry
-177.72x
Market
27.98x
RNTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.69x
Industry
4.05x
RNTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RNTX's financial health
Profit margin
Revenue
$0.0
Net Income
-$41.0M
Profit Margin
0%
RNTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$62.2M
Liabilities
$7.8M
Debt to equity
0.14
RNTX's short-term assets ($13.66M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RNTX's short-term assets ($13.66M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RNTX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
RNTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.8M
Investing
$0.0
Financing
$1.0k
RNTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RNTX vs Biotech Stocks
Rein Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.